Regulatory T cells (Tregs) play a pivotal role in suppressing specific antiviral immune responses during the progression of chronic hepatitis B virus infection (CHB) as well as tumorigenesis. Programmed death-1 ligand-1 (PD-L1) expressed on Tregs can transduce an inhibitory signal into effector T cells through interacting with programmed death-1 (PD-1). However, in CHB patients, the clinical significance of PD-L1 expression on Tregs has not been clearly described. This study investigated the frequency of circulating Tregs and PD-L1 expression on Tregs and analyzed their correlations with clinical parameters. The data show that both the frequency of CD4+CD25+FoxP3+ Tregs and PD-L1 expression on Tregs in the peripheral blood increased significantly in CHB patients when compared with healthy controls. At the same time, it is shown that PD-L1 expression on Tregs was positively correlated with the percentage of Tregs in CHB patients. Moreover, the results demonstrated that both Treg frequency and PD-L1 expression on Tregs positively correlated with the levels of alanine aminotransaminase (ALT) and aspartate aminotransferase (AST), both of which are indicators of the extent of liver injury. Taken together, these findings suggest that PD-L1 on Tregs might contribute to progression of hepatitis B virus infection through mediating the inhibitory function of Tregs. Thereby, blockade of interaction between Treg-expressing PD-L1 and PD-1 on effector T cells may be adopted as a potential therapeutic approach in CHB.
Get full access to this article
View all access options for this article.
References
1.
AlatrakchiN, and KozielM. Regulatory T cells and viral liver disease. J Viral Hepat, 2009; 16:223–229.
2.
BarberDL, WherryEJ, MasopustD, et al.Restoring function in exhausted CD8 T cells during chronic viral infection. Nature, 2006; 439:682–687.
3.
BarbiJ, PardollD, and PanF. Treg functional stability and its responsiveness to the microenvironment. Immunol Rev, 2014; 259:115–139.
4.
BengschB, MartinB, and ThimmeR. Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation. J Hepatol, 2014; 61:1212–1219.
5.
BettiniM, and VignaliDA. Regulatory T cells and inhibitory cytokines in autoimmunity. Curr Opin Immunol, 2009; 21:612–618.
6.
CaiG, NieX, LiL, et al.B and T lymphocyte attenuator is highly expressed on intrahepatic T cells during chronic HBV infection and regulates their function. J Gastroenterol, 2013; 48:1362–1372.
7.
ChenJH, PerryCJ, TsuiYC, et al.Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection. Nat Med, 2015; 21:327–334.
8.
CretneyE, KalliesA, and NuttSL. Differentiation and function of Foxp3(+) effector regulatory T cells. Trends Immunol, 2013; 34:74–80.
9.
DolinaJS, BracialeTJ, and HahnYS. Liver-primed CD8+ T cells suppress antiviral adaptive immunity through galectin-9-independent T-cell immunoglobulin and mucin 3 engagement of high-mobility group box 1 in mice. Hepatology, 2014; 59:1351–1365.
10.
FerrisRL, LuB, and KaneLP. Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion. J Immunol, 2014; 193:1525–1530.
11.
FourcadeJ, SunZ, PaglianoO, et al.CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res, 2012; 72:887–896.
12.
FranzeseO, KennedyPT, GehringAJ, et al.Modulation of the CD8+-T-cell response by CD4+CD25+ regulatory T cells in patients with hepatitis B virus infection. J Virol, 2005; 79:3322–3328.
13.
FuJ, XuD, LiuZ, et al.Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology, 2007; 132:2328–2339.
14.
GengS, ZhongY, WangS, et al.Amiloride enhances antigen specific CTL by faciliting HBV DNA vaccine entry into cells. PloS One, 2012; 7:e33015.
15.
GototJ, GottschalkC, LeopoldS, et al.Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo. Proc Natl Acad Sci U S A, 2012; 109:10468–10473.
16.
HaymakerC, WuR, BernatchezC, et al.PD-1 and BTLA and CD8(+) T-cell “exhaustion” in cancer: “exercising” an alternative viewpoint. Oncoimmunology, 2012; 1:735–738.
17.
HuangYH, ZhuC, KondoY, et al.CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature, 2015; 517:386–390.
18.
KaufmannDE, and WalkerBD. PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. J Immunol, 2009; 182:5891–5897.
19.
KeirME, ButteMJ, FreemanGJ, et al.PD-1 and its ligands in tolerance and immunity. Ann Rev Immunol, 2008; 26:677–704.
20.
KitazawaY, FujinoM, WangQ, et al.Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses. Transplantation, 2007; 83:774–782.
21.
LaiCL, and YuenMF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology, 2013; 57:399–408.
22.
LiuJ, ZhangE, MaZ, et al.Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog, 2014; 10:e1003856.
23.
MaierH, IsogawaM, FreemanGJ, et al.PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J Immunol, 2007; 178:2714–2720.
24.
NanXP, ZhangY, YuHT, et al.Circulating CD4+CD25high regulatory T cells and expression of PD-1 and BTLA on CD4+ T cells in patients with chronic hepatitis B virus infection. Viral Immunol, 2010; 23:63–70.
25.
NebbiaG, PeppaD, SchurichA, et al.Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection. PloS One, 2012; 7:e47648.
26.
PapatheodoridisGV, ChanHL, HansenBE, et al.Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol, 2015; 62:956–967.
27.
PaukenKE, and WherryEJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol, 2015; 36:265–276.
28.
PengG, LiS, WuW, et al.PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol, 2008; 45:963–970.
29.
PowlesT, EderJP, FineGD, et al.MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature, 2014; 515:558–562.
30.
RingelhanM, O'ConnorT, ProtzerU, et al.The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets. J Pathol, 2015; 235:355–367.
31.
SchurichA, KhannaP, LopesAR, et al.Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology, 2011; 53:1494–1503.
32.
StoopJN, van der MolenRG, BaanCC, et al.Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology, 2005; 41:771–778.
33.
TaoR, WangL, MurphyKM, et al.Regulatory T cell expression of herpesvirus entry mediator suppresses the function of B and T lymphocyte attenuator-positive effector T cells. J Immunol, 2008; 180:6649–6655.
34.
TumehPC, HarviewCL, YearleyJH, et al.PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature, 2014; 515:568–571.
35.
WangW, LauR, YuD, et al.PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol, 2009; 21:1065–1077.
36.
XibingG, XiaojuanY, and JuanhuaW. PD-1 expression on CTL may be related to more severe liver damage in CHB patients with HBV genotype C than in those with genotype B infection. J Viral Hepat, 2013; 20:e1–2.
37.
XuD, FuJ, JinL, et al.Circulating and liver resident CD4+ CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol, 2006; 177:739–747.
38.
XuP, ChenYJ, ChenH, et al.The expression of programmed death-1 in circulating CD4+ and CD8+ T cells during hepatitis B virus infection progression and its correlation with clinical baseline characteristics. Gut Liver, 2014; 8:186–195.
39.
YangP, LiQJ, FengY, et al.TGF-beta-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell, 2012; 22:291–303.
